David Segal, PhD is a Professor of Biochemistry and Molecular Medicine in the SOM with 20 years of experience engineering zinc finger, TALE and CRISPR/Cas as molecular tools for epigenetic editing. He develops tools for targeted epigenetic reprograming of specific cancer genes. A CRISPR activation screen identified GAS1 as a potential therapeutic gene for triple negative breast cancer. Ongoing work is investigating if these tools can be used not only for gene discovery but also therapeutic gene regulation.

Trainees:

• Jose Antonio Gomez